KR20210115294A - Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout - Google Patents
Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout Download PDFInfo
- Publication number
- KR20210115294A KR20210115294A KR1020200030851A KR20200030851A KR20210115294A KR 20210115294 A KR20210115294 A KR 20210115294A KR 1020200030851 A KR1020200030851 A KR 1020200030851A KR 20200030851 A KR20200030851 A KR 20200030851A KR 20210115294 A KR20210115294 A KR 20210115294A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- male
- decreased
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 title claims description 53
- 241000209140 Triticum Species 0.000 title claims description 17
- 235000021307 Triticum Nutrition 0.000 title claims description 17
- 208000024891 symptom Diseases 0.000 title abstract description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 52
- 229940088597 hormone Drugs 0.000 claims abstract description 26
- 239000005556 hormone Substances 0.000 claims abstract description 26
- 229960003604 testosterone Drugs 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 19
- 229940076439 wheat sprout extract Drugs 0.000 claims abstract description 11
- 241001668545 Pascopyrum Species 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 230000003247 decreasing effect Effects 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000009245 menopause Effects 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000000580 secretagogue effect Effects 0.000 claims description 5
- 206010051482 Prostatomegaly Diseases 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010060800 Hot flush Diseases 0.000 claims description 2
- 206010058359 Hypogonadism Diseases 0.000 claims description 2
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000007103 stamina Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 21
- 230000028327 secretion Effects 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000002381 testicular Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000007423 decrease Effects 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- 230000032683 aging Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000001548 androgenic effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 101150017665 CYP11A1 gene Proteins 0.000 description 5
- 101150051357 CYP17A1 gene Proteins 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- -1 fluoroalkane Chemical compound 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 206010002261 Androgen deficiency Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RZRPTBIGEANTGU-UHFFFAOYSA-N -Androst-4-ene-3,11,17-trione Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)=O)C4C3CCC2=C1 RZRPTBIGEANTGU-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- RZRPTBIGEANTGU-IRIMSJTPSA-N adrenosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RZRPTBIGEANTGU-IRIMSJTPSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Abstract
Description
본 발명은 밀싹 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 남성 고환 세포에서 남성호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론의 분비 촉진 효과를 나타내는 밀싹 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating androgenic syndrome comprising a wheat germ extract, and more particularly, to a composition for preventing or treating androgenic syndrome, including a wheat germ extract that increases the expression of androgen-related genes and proteins in male testicular cells and exhibits a testosterone secretion promoting effect It relates to a composition for preventing or treating male menopausal syndrome.
우리나라 65세 이상 노인 인구는 2000년도에 이미 7%을 돌파하여 노령화 사회에 진입하게 되었고 현재 14%을 넘어서서 본격적인 노령사회가 시작되고 있다. 문제는 노령화 사회에서 노령사회로 넘어가는 기간이 기존의 선진 국가들이 80년에서 100년이 소요되었던 것에 비해 우리나라는 20년도 채 되지 않아 너무 급격하게 노인인구가 증가하게 된다는 사실이다. 노령사회가 되면 사회 정책적인 면에서도 많은 변화가 있겠지만 의료면에서도 많은 변화를 예측할 수가 있다. 비뇨기과적으로는 전립선 비대증이나 전립선암과 성기능장애 및 남성갱년기 증상 같은 남성호르몬이 관련된 질환들이 증가할 것으로 보인다.The elderly population aged 65 and over in Korea already exceeded 7% in 2000, entering an aging society, and now exceeding 14%, a full-scale aging society is starting. The problem is that the transition period from an aging society to an aging society takes less than 20 years in Korea, compared to 80 to 100 years in the existing advanced countries, so the elderly population is increasing too rapidly. As we become an aging society, there will be many changes in social policy, but we can predict many changes in the medical field as well. In terms of urology, diseases related to male hormones such as enlarged prostate, prostate cancer, sexual dysfunction, and male menopause symptoms are expected to increase.
여성은 여성호르몬이 월중변화를 보이다가 50대 초반에 폐경이 되면서 완전히 바닥으로 내려오지만 남성에서는 여성과는 달리 나이가 들면서 서서히 감소하기 때문에 노인이 되더라도 일정 수준의 호르몬은 계속 분비가 되기 때문에 여성에서처럼 갱년기 증상이 뚜렷하거나 또한 모든 사람에서 나타나는 것은 아니다. 그래서 남성갱년기를 male climacteric, andropause외에도 PADAM(partial androgen deficiency in aging male)으로도 부르고 있다.In women, female hormones show monthly changes and then completely drop to the bottom at menopause in their early 50s, but unlike women, in men, it gradually decreases with age. Menopause symptoms are not obvious or present in all people. Therefore, male menopause is also called PADAM (partial androgen deficiency in aging male) in addition to male climacteric and andropause.
노화와 관련된 테스토스테론(testosterone) 저하는 그 시작연령, 진행속도, 저하정도의 개인차가 큰 편이다. 대체로 50세 이후 혈중 테스토스테론 치는 1년에 1% 정도 감소한다. 이 같은 감소는 60세 이전에는 7%에서만 발견되지만 60세 이후에는 20% 정도로 증가한다. 그러나 노화에 따른 SHBG의 증가로 생리학적으로 이용가능한 테스토스테론은 더욱 감소하므로 실제 PADAM의 빈도는 이보다 더 흔할 것으로 추정된다. 노화에 따른 또 다른 변화는 남성호르몬의 일중 변동이 없어져서 24시간 내내 낮은 농도를 유지한다는 것이다. The age-related decline in testosterone has large individual differences in the onset age, progression rate, and degree of decline. In general, after
그런데 남성갱년기 증상은 테스토스테론의 감소로 인해서만 나타나는 것은 아니다. 과거에는 남성호르몬의 결핍만이 그 원인인 것으로 생각하였던 증상의 상당부분이 다른 호르몬의 변화에 기인함이 밝혀지고 있다. 성장호르몬은 사춘기 이후에 매 10년마다 약 14% 정도씩 생산이 감소하고 있다. 성장 호르몬에 의해 생산이 조절되는 IGF-1 (insulin-like growth factor-1)도 함께 감소한다. 저혈당과 암 시야에 반응해 송과선(pineal gland)에서 분비되는 멜라토닌도 노화에 따라 감소한다. However, menopausal symptoms are not only caused by a decrease in testosterone. In the past, it is revealed that a significant part of the symptoms that were thought to be the only cause of testosterone deficiency are due to changes in other hormones. Growth hormone production decreases by about 14% every 10 years after puberty. IGF-1 (insulin-like growth factor-1), whose production is regulated by growth hormone, also decreases. Melatonin, secreted by the pineal gland in response to hypoglycemia and dark vision, also decreases with aging.
테스토스테론을 비롯하여 다양한 호르몬의 저하에 따라 성적 욕구감소, 발기능력의 저하, 우울함과 짜증을 수반하는 기분의 저하, 기억력 감소, 제지방량의 감소, 체모의 감소와 피부노화, 골밀도 감소, 내장지방 증가 등이 나타난다고 한다(대한 성학회. 제1회 의사를 위한 성치료 교육과정 2003. 11.). 이러한 남성 갱년기의 원인은 기타 환경적 요인 외에도 내분비계의 쇠태에 있어 그 동안은 남성 호르몬의 보충치료가 주된 치료요법으로 알려져 왔다. 남성 호르몬 보충요법은 먹는 약이나 바르는 제제, 붙이는 패치형 제제, 주사요법 등이 있다.Decreased sexual desire, decreased erection ability, decreased mood accompanied by depression and irritability, decreased memory, decreased fat mass, decreased body hair and skin aging, decreased bone density, increased visceral fat, etc. (The Korean Society of Sexuality. The 1st Sex Therapy Curriculum for Doctors 2003. 11.). In addition to other environmental factors, the cause of male menopause is the decline of the endocrine system. Male hormone replacement therapy includes oral medications, topical formulations, patch-type formulations, and injection therapy.
그러나, 남성 호르몬 요법을 통한 남성 갱년기 증상의 치료는 전립선의 크기를 증가시켜 이미 발생한 전립선암 크기를 증가시키거나 수면 중 무호흡증의 악화, 여성형 유방 발생, 적혈구증가증 발생, 심혈관질환 위험도 증가 등의 부작용이 따를 수 있다. 또한, 이러한 호르몬 치료요법은 남성 갱년기 증상의 근본적인 발병 원인을 치료하지는 못하며, 남자라면 누구나 나이가 들면서 남성 갱년기 증세를 겪게 되므로 그 예방이 무엇보다 중요하다. 따라서, 이러한 부작용이 없이 증상의 진행과정을 막아줄 수 있는 예방제 및 치료제의 개발이 절실히 요구되는 실정이다.However, treatment of male menopause symptoms through male hormone therapy increases the size of the prostate and increases the size of prostate cancer that has already occurred or has side effects such as worsening of apnea during sleep, gynecomastia, erythrocytosis, and increased risk of cardiovascular disease. can follow In addition, these hormone therapy does not treat the root cause of the symptoms of male menopause, and prevention is most important because all men experience androgenic symptoms as they age. Therefore, there is an urgent need to develop a preventive agent and a therapeutic agent that can block the progression of symptoms without such side effects.
한편, 밀싹은 화본과 외떡잎 식물에 해당하며, 밀싹과 같은, 밀, 보리 등 곡류의 새싹은 마디 세포가 생겨 줄기로 자라기 전에는 채소와 같은 영양성분을 가지며 알곡과 성분이 전혀 다르다고 알려져 있다. 밀싹은 다양한 비타민과 82종의 미네랄과 30종의 효모, 17가지의 아미노산을 함유하고 있다고 알려져 있다. On the other hand, wheat sprouts correspond to flowering plants and monocotyledonous plants, and it is known that sprouts of grains such as wheat and barley have the same nutritional components as vegetables and are completely different from grains before node cells are formed and grow into stems. Wheatgrass is known to contain various vitamins, 82 kinds of minerals, 30 kinds of yeast, and 17 kinds of amino acids.
또한, 한국 공개특허 제10-2016-0062401호에는 밀싹 추출물 혼합액이 피부주름개선에 효과가 있다는 것이 보고된 바 있지만, 밀싹 추출물이 남성 호르몬 분비장애와 관련된 남성 갱년기 증후군에 효과를 나타내는지 여부에 대해서는 아직까지 보고된 바가 없다.In addition, Korean Patent Application Laid-Open No. 10-2016-0062401 has reported that the wheat sprout extract mixture is effective in improving skin wrinkles, but whether the wheat sprout extract is effective on androgenic syndrome related to male hormone secretion disorder is not known. Nothing has been reported yet.
이에, 본 발명자는 남성 갱년기 증후군 개선 효능이 뛰어난 새로운 천연물 유래의 소재를 개발하고자 예의 연구를 거듭한 결과, 밀싹 추출물이 남성 호르몬 관련 유전자의 발현을 증가시키고 테스토스테론의 분비량을 증가시켜 남성 갱년기 증후군의 예방 또는 치료 소재로서 활용이 될 수 있음을 발견하고 본 발명을 완성하였다. Accordingly, the present inventors have repeatedly researched to develop a new natural material-derived material with excellent efficacy in improving the androgenic syndrome, and as a result, wheatgrass extract increases the expression of male hormone-related genes and increases the secretion of testosterone to prevent androgenic syndrome Alternatively, it was found that it can be utilized as a therapeutic material and completed the present invention.
따라서, 본 발명의 목적은 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 치료용 약학적 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating male menopausal syndrome comprising wheatgrass extract as an active ingredient.
본 발명의 다른 목적은 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a food composition for preventing or improving male menopausal syndrome comprising wheatgrass extract as an active ingredient.
본 발명의 다른 목적은 밀싹 추출물을 유효성분으로 포함하는 남성 호르몬 분비 촉진제를 제공하는 것이다. Another object of the present invention is to provide a male hormone secretagogue comprising wheatgrass extract as an active ingredient.
상기한 본 발명의 목적을 달성하기 위하여 본 발명은 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 치료용 약학적 조성물을 제공한다. In order to achieve the above object of the present invention, the present invention provides a pharmaceutical composition for preventing or treating male menopausal syndrome comprising wheatgrass extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a food composition for preventing or improving male menopausal syndrome comprising wheatgrass extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 밀싹 추출물을 유효성분으로 포함하는 남성 호르몬 분비 촉진제를 제공한다. In order to achieve another object of the present invention, the present invention provides a male hormone secretagogue comprising wheatgrass extract as an active ingredient.
이하, 본 발명에 대하여 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 치료용 약학적 조성물을 제공한다. The present invention provides a pharmaceutical composition for preventing or treating male menopausal syndrome comprising wheatgrass extract as an active ingredient.
본 발명의 일실시예에 따르면, 밀싹 추출물은 남성 고환 세포주에서 남성호르몬의 생성에 관여하는 주요 효소들의 mRNA와 단백질의 발현을 증가시켰으며, 직접적으로 테스토스테론 분비를 촉진하는 효과를 나타내는 것으로 확인되었다. According to an embodiment of the present invention, the wheat germ extract increased the expression of mRNA and protein of major enzymes involved in the production of male hormones in male testis cell lines, and it was confirmed that it showed the effect of directly promoting the secretion of testosterone.
본 발명에서 상기 밀싹 추출물은 광의로는 밀싹 자체를 동물에게 투여할 수 있도록 제형화 된 밀싹 가공물, 예컨대, 밀싹 가루도 포함하는 의미를 갖는다. 비록 본 발명에서 밀싹 추출물로 실험을 진행하긴 하였으나, 밀싹 자체와 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상 가능할 것이다.In the present invention, the wheat sprout extract has a meaning including wheat sprout itself, for example, wheat sprout powder formulated to be administered to an animal in a broad sense. Although the experiment was carried out with wheat sprout extract in the present invention, it will be expected by those skilled in the art that the desired effect can be achieved even in the same form as wheat sprout itself.
본 발명에 있어서, 상기 밀싹 추출물은 밀싹의 물, 유기용매 또는 이들의 혼합물을 추출 용매로서 이용하여 추출된 것일 수 있다. 이 때 사용되는 유기용매의 종류나 물과 유기용매의 혼합 비율은 특별히 제한되지 않는다. In the present invention, the wheat sprout extract may be extracted using water, an organic solvent, or a mixture thereof as an extraction solvent. In this case, the type of the organic solvent used or the mixing ratio of water and the organic solvent is not particularly limited.
예를 들어, 상기 유기용매는 저급 알코올, 헥산, 아세톤, 에틸 아세테이트, 클로로포름, 및 디에틸에테르로 이루어진 군으로부터 선택된 하나 이상의 용매일 수 있다. 상기 저급 알코올은 탄소수 1 내지 6의 알코올일 수 있다. 예를 들어, 저급 알코올로는 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜 등을 이용할 수 있다. 유기용매는 이 외에도 아세트산, DMFO(dimethyl-formamide), DMSO(dimethyl sulfoxide) 등의 극성 용매, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 2,2,4-트리메틸펜탄, 데칸, 사이클로헥산, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소 및 THF(Tetrahydrofuran) 등의 비극성 용매를 사용할 수도 있다. 바람직하게는, 본 발명에서 상기 밀싹 추출물은 극성 용매에 의한 추출물일 수 있으며, 더 바람직하게는 물 또는 탄소수 1 내지 6개의 알코올 추출물일 수 있으며, 가장 바람직하게는 물 추출물일 수 있다. For example, the organic solvent may be one or more solvents selected from the group consisting of lower alcohol, hexane, acetone, ethyl acetate, chloroform, and diethyl ether. The lower alcohol may be an alcohol having 1 to 6 carbon atoms. For example, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol may be used as the lower alcohol. Organic solvents include acetic acid, polar solvents such as dimethyl-formamide (DMFO), dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, and decane. , cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene , benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and a non-polar solvent such as tetrahydrofuran (THF) may be used. Preferably, the wheatgrass extract in the present invention may be an extract using a polar solvent, more preferably water or an alcohol extract having 1 to 6 carbon atoms, and most preferably a water extract.
본 발명 추출물은 공지의 천연물 추출법으로 추출될 수 있다. 예를 들어 냉침추출, 열수추출, 용매추출, 초음파 추출, 환류냉각 추출, 가열 추출법으로 추출할 수 있으며, 바람직하게는 열수추출, 용매추출 또는 환류 냉각 추출법으로 추출할 수 있으며, 더 바람직하게는 열수추출 또는 용매추출일 수 있으며, 가장 바람직하게는 열수추출일 수 있다. 또한, 상기 추출은 1회 내지 10회, 바람직하게는 2회 내지 7회 반복 추출할 수 있다.The extract of the present invention may be extracted by a known natural product extraction method. For example, extraction may be performed by cold extraction, hot water extraction, solvent extraction, ultrasonic extraction, reflux cooling extraction, or heating extraction method, preferably hot water extraction, solvent extraction or reflux cooling extraction method, and more preferably, hot water extraction It may be extraction or solvent extraction, most preferably hot water extraction. In addition, the extraction may be repeated 1 to 10 times, preferably 2 to 7 times.
본 명세서에서 밀싹을 언급하면서 사용되는 용어 '추출물'은 밀싹에 추출용매를 처리하여 얻은 조추출물 뿐만 아니라 밀싹 추출물의 가공물도 포함한다. 예를 들어, 밀싹 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The term 'extract' used while referring to wheat sprout in the present specification includes not only the crude extract obtained by treating wheat sprout with an extraction solvent, but also the processed product of the wheat sprout extract. For example, the wheatgrass extract may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying.
본 발명에서 상기 남성 갱년기 증후군이란 신체 노화에 따라 남성에게서 발생하는 다양한 생리학적 현상을 의미하는 것으로서 이는 남성 호르몬, 성장 호르몬 등 다양한 호르몬의 분비 감소에 의한 내인적인 요인과 고립감, 소외감, 박탈감 등 개인을 둘러싼 다양한 환경적인 영향에 따른 심리적인 요인들이 복합적으로 작용하여 나타나게 된다. 상기 갱년기 증후군은 이에 제한되는 것은 아니나, 성선기능저하증, 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소 및 테스토스테론 저하증으로 이루어진 군에서 선택될 수 있으며, 바람직하게는 테스토스테론 저하증일 수 있다. In the present invention, the male menopause syndrome refers to various physiological phenomena that occur in men according to physical aging, which is an intrinsic factor caused by a decrease in secretion of various hormones such as male hormone and growth hormone, and a feeling of isolation, alienation, and deprivation. Psychological factors according to the various environmental influences surrounding it appear as a result of a complex action. The menopausal syndrome is not limited thereto, but hypogonadism, enlarged prostate, lower urinary tract symptoms, irritability, emotional instability, depression, hot flushes, sleep disorders, decreased vitality, decreased work capacity, decreased libido, erectile dysfunction, decreased energy , may be selected from the group consisting of reduced physical strength, reduced exercise capacity, reduced body hair and hypotestosterone, and preferably may be hypotestosterone.
한편, 본 명세서에서 용어 '유효성분으로 포함하는'이란 밀싹 추출물 또는 밀싹 분말의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명의 한 구체예에서, 본 발명의 조성물 내에서 밀싹 추출물은 예를 들어, 0.001 mg/kg 이상, 바람직하게는 0.1 mg/kg 이상, 보다 바람직하게는 10 mg/kg 이상, 보다 더 바람직하게는 100 mg/kg 이상, 보다 더욱 더 바람직하게는 250 mg/kg 이상, 가장 바람직하게는 0.1 g/kg 이상 포함된다. 밀싹 추출물 또는 밀싹 분말은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 밀싹 추출물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.Meanwhile, in the present specification, the term 'comprising as an active ingredient' means including an amount sufficient to achieve the efficacy or activity of wheat sprout extract or wheat sprout powder. In one embodiment of the present invention, the wheatgrass extract in the composition of the present invention is, for example, 0.001 mg/kg or more, preferably 0.1 mg/kg or more, more preferably 10 mg/kg or more, even more preferably is 100 mg/kg or more, even more preferably 250 mg/kg or more, and most preferably 0.1 g/kg or more. Wheatgrass extract or wheatgrass powder is a natural product, and since there is no side effect to the human body even when administered in excess, the upper quantitative limit of the wheatgrass extract included in the composition of the present invention can be selected and implemented by those skilled in the art within an appropriate range.
본 발명의 약학적 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes an excipient, a disintegrant, a sweetener, a binder, a coating agent, a swelling agent, a lubricant, A lubricant or flavoring agent may be used.
상기 약학적 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약학적 조성물로 바람직하게 제제화할 수 있다. The pharmaceutical composition may be preferably formulated as a pharmaceutical composition by including one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
상기 약학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. Formulations of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions. For formulation in the form of, for example, tablets or capsules, the active ingredient may be combined with an orally, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or required, suitable binders, lubricants, disintegrants and color-developers may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, emulsion, etc., pills, capsules, granules or tablets.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 성분에 따라 바람직하게 제제화 할 수 있다. Furthermore, it can be preferably formulated according to the ingredients using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA by an appropriate method in the field.
본 발명의 약학적 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration. .
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약학적 조성물의 1일 투여량은 0.001-10g/㎏이다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity of the patient, An ordinarily skilled physician can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dose of the pharmaceutical composition of the present invention is 0.001-10 g/kg.
본 발명의 약학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화 함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension, or emulsion in oil or an aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.
본 발명은 또한 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 제공한다. The present invention also provides a food composition for preventing or improving male menopausal syndrome comprising wheatgrass extract as an active ingredient.
본 발명에 따른 식품 조성물은 상기 약학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, sweets, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gums, ice cream, vitamin complexes, health supplements etc.
본 발명의 식품 조성물은 유효성분으로서 밀싹 추출물 또는 밀싹 분말뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 밀싹 추출물 또는 밀싹 분말 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may include not only wheatgrass extract or wheatgrass powder as an active ingredient, but also ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. include Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose, oligosaccharides and the like; and polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatine, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is prepared as a drink or beverage, citric acid, high fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included in addition to the wheatgrass extract or wheatgrass powder of the present invention. can
본 발명은 상기 밀싹 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 밀싹 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 밀싹 추출물 또는 밀싹 분말의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food comprising a food composition for preventing or improving male menopausal syndrome comprising the wheatgrass extract as an active ingredient. A health functional food is a food prepared by adding wheatgrass extract to food ingredients such as beverages, teas, spices, gum, and confectionery, or by encapsulating, powdering, or suspension, etc. However, unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long period of time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be ingested on a daily basis. The amount of wheatgrass extract or wheatgrass powder added in such a health functional food cannot be defined uniformly because it varies depending on the type of health functional food, but it can be added within a range that does not impair the original taste of the food, and is added to the target food. It is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of a health functional food in the form of pills, granules, tablets or capsules, it is usually added in an amount of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
본 발명은 또한, 밀싹 추출물을 유효성분으로 포함하는 남성 호르몬 분비 촉진제를 제공한다.The present invention also provides a male hormone secretagogue comprising wheatgrass extract as an active ingredient.
본 발명의 상기 '남성 호르몬'은 남성 고환의 간세포에서 분비되는 안드로겐(androgen)으로, 전립선이나 음경 등의 발육을 촉진시키고, 남성의 제2차 성징을 나타내며, 뇌하수체 전엽의 생식선자극 호르몬의 분비를 억제하는 역할을 한다. 본 발명에서 남성 호르몬은 테스토스테론, 소변에 함유된 안드로스테론(androsterone) 또는 디하이드로에피안드로스테론(dehydroepiandrosterone), 부신피질에서 분비되는 아드레노스테론(adrenosterone) 등의 천연 호르몬일 수 있다. 보다 바람직하게는 테스토스테론일 수 있다.The 'male hormone' of the present invention is an androgen secreted from the hepatocytes of the male testis, and promotes the growth of the prostate or penis, exhibits male secondary sexual characteristics, and inhibits the secretion of gonadotropin from the anterior pituitary. acts as a deterrent. In the present invention, the male hormone may be a natural hormone such as testosterone, androsterone or dehydroepiandrosterone contained in urine, and adrenosterone secreted from the adrenal cortex. More preferably, it may be testosterone.
본 발명이 제공하는 밀싹 추출물은 남성 호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론 분비 촉진 효과를 나타내어 남성 갱년기 증후군 치료제 또는 개선용 식품 개발에 매우 유용하게 활용이 될 수 있다. The wheatgrass extract provided by the present invention increases the expression of male hormone-related genes and proteins and exhibits a testosterone secretion promoting effect, so that it can be very usefully used in the development of food for treatment or improvement of male menopausal syndrome.
도 1은 마우스 고환 세포주 TM3에 밀싹 열수 추출물을 농도별로 24시간 동안 처리한 후 남성 호르몬 관련 유전자 (StAR, Cyp11a1, Cyp17a1)의 mRNA 발현 변화를 qRT-PCR로 측정한 결과이다.
도 2는 마우스 고환 세포주 TM3에 밀싹 열수 추출물을 농도별로 24시간 동안 처리한 후 남성 호르몬 관련 단백질 (StAR, Cyp11a1, Cyp17a1)의 발현량 변화를 웨스턴 블롯으로 측정한 결과이다.
도 3은 마우스 고환 세포주 TM3에 밀싹 열수 추출물을 농도별로 48시간 동안 처리한 후, 세포 배양액 내의 테스토스테론 양을 ELISA로 측정하여 밀싹 열수 추출물의 테스토스테론 분비 촉진 효과를 확인한 도면이다. 1 is a result of measuring the change in mRNA expression of male hormone-related genes (StAR, Cyp11a1, Cyp17a1) by qRT-PCR after treating the mouse testis cell line TM3 with hot wheatgrass extract at different concentrations for 24 hours.
2 is a result of measuring the expression level of male hormone-related proteins (StAR, Cyp11a1, Cyp17a1) by Western blot after treating the mouse testicular cell line TM3 with hot wheatgrass extract at different concentrations for 24 hours.
3 is a view confirming the testosterone secretion promoting effect of the hot wheatgrass extract by measuring the amount of testosterone in the cell culture solution by ELISA after treating the mouse testis cell line TM3 with hot water extract of wheat sprout at each concentration for 48 hours.
이하, 본 발명을 하기 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명이 이들에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are only for illustrating the present invention, and the present invention is not limited thereto.
실시예 1: 실험의 준비Example 1: Preparation of experiments
마우스 고환 세포주인 TM3 세포 (mouse leydig cell, ATCC￠c CRL-1714™, mouse testis)를 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 5%, fetal bovine serum 2.5% 에서 37℃, 5% CO2, 95% O2 조건으로 배양하였다. The mouse testis cell line, TM3 cells (mouse leydig cell, ATCC￠c CRL-1714™, mouse testis) was mixed with a 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's Medium,
밀싹 열수 추출물을 제조하기 위해서 밀싹을 자연 건조하여 수분이 0~10% 일 때 고형분 대비 20배의 증류수를 첨가하여 열수추출물 (HE, heat water extraction)을 제조하였다. 열수추출물은 각각 100℃ 및 80℃에서 3시간 동안 환류냉각추출기를 이용하여 추출하였다. 추출물은 불순물울 제거하기 위하여 여과지를 이용하여 여과시켰다. 여과된 용액은 감압농축기를 사용하여 강압농축한 뒤, 동결건조기로 건조하여 분석용 시료로 사용하였다. To prepare a wheat sprout hot water extract, wheat sprout was naturally dried and distilled water 20 times greater than the solid content was added when the moisture was 0 to 10% to prepare a heat water extract (HE). The hot water extract was extracted using a reflux cooling extractor at 100°C and 80°C, respectively, for 3 hours. The extract was filtered using filter paper to remove impurities. The filtered solution was concentrated under reduced pressure using a vacuum concentrator, dried with a freeze dryer, and used as a sample for analysis.
상기 TM3 세포에 상기 제조한 밀싹 열수 추출물 동결건조 분말을 멸균한 물 (DDW, distilled deionized water)로 충분히 녹여준다. 각각 0, 1, 10, 25, 50ug/ml의 농도로 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 1%, fetal bovine serum 0.5% 에 녹여서 세포에 처리하였다. In the TM3 cells, the prepared freeze-dried powder of the hot water extract of wheatgrass was sufficiently dissolved in sterile water (DDW, distilled deionized water). Cells were treated by dissolving them in a 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's Medium,
실시예 2: 남성호르몬 관련 유전자 및 단백질 발현량 평가Example 2: Evaluation of male hormone-related gene and protein expression level
상기 실시예 1에서 추출물 분말을 24시간 처리한 세포에서 mRNA를 추출하였고 (Favogen 회사), Rotor-Gene QPCR 기계를 (Qiagen 회사)사용하여 qPCR을 실시하였으며, 조건은 95℃, 5분간 denaturation하고, 95℃, 5초간 그리고 60℃, 5초간 40 cycles을 반응시켜서 Cyp11a1, Cyp17a1, StAR 발현량을 측정하였다. 하우스키핑 유전자(House keeping gene)인 18S rRNA를 이용하여 정량화하였다. qPCR에 사용한 프라이머의 서열정보는 하기 표 1에 나타내었다.In Example 1, mRNA was extracted from the cells treated with the extract powder for 24 hours (Favogen Company), and qPCR was performed using a Rotor-Gene QPCR machine (Qiagen Company), conditions 95° C., denaturation for 5 minutes, Cyp11a1, Cyp17a1, and StAR expression levels were measured by reacting 40 cycles at 95°C for 5 seconds and 60°C for 5 seconds. It was quantified using 18S rRNA, which is a house keeping gene. Sequence information of primers used for qPCR is shown in Table 1 below.
TM3 세포에 밀싹 열수 추출물을 멸균한 물 (DDW, distilled deionized water)로 잘 녹인다. 각각 0, 1, 10, 25, 50ug/ml의 농도로 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 1%, fetal bovine serum 0.5%에 녹여서 48시간동안 처리한 뒤, 세포를 수득하여 통상적인 방법으로 웨스턴블랏(western blot)실험 을 실시하였다.Dissolve the hot wheatgrass extract in TM3 cells with sterile water (DDW, distilled deionized water). Dissolve in a 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's Medium,
세포를 용해해서 총단백질을 추출한 다음, SDS-PAGE (Sodium dodecyl su lfate polyacrylamide gel electrophoresis)을 통해서 분리하여서, NC (nitrocellulose membrane)에 블랏한 후, 1차 항체(Cyp11a1, Cyp17a1, StAR,β-actin)를 4℃에서 12~16시간 반응시켰다. TBST(tris-buffered saline tween 20) washing buffer로 충분히 washing 하였다. 2차 항체를 실온에서 1시간 동안 반응시키고 ECL(enhanced chemiluminesc ence)로 발색하여 결과를 도출하였다. 각각의 실험군에 대한 Cyp11a1, Cyp17a1, StAR 단백질 발현량을 측정하였다. Cells were lysed to extract total protein, and then separated through SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis), blotted on NC (nitrocellulose membrane), and primary antibodies (Cyp11a1, Cyp17a1, StAR, β-actin) ) was reacted at 4° C. for 12 to 16 hours. It was sufficiently washed with TBST (tris-buffered saline tween 20) washing buffer. The secondary antibody was reacted at room temperature for 1 hour, and the result was obtained by developing color with ECL (enhanced chemiluminescence). Cyp11a1, Cyp17a1, StAR protein expression levels for each experimental group were measured.
이에 대한 결과를 도 1 및 도 2에 나타내었다. The results for this are shown in FIGS. 1 and 2 .
도 1 및 도 2에 나타낸 바와 같이, 마우스 고환 세포주 TM3에 밀싹 열수 추출물을 처리한 결과, 남성호르몬 관련 유전자 및 단백질의 발현량이 미처리 대조군 대비 현저하게 증가하는 것을 확인할 수 있었다. As shown in FIGS. 1 and 2 , as a result of treating the hot wheatgrass extract in the mouse testicular cell line TM3, it was confirmed that the expression levels of male hormone-related genes and proteins significantly increased compared to the untreated control group.
실시예 3: 고환 세포주 TM3에서 테스토스테론의 분비량 평가Example 3: Evaluation of testosterone secretion in testicular cell line TM3
밀싹 열수 추출물이 남성 호르몬인 테스토스테론(testosterone) 생성에 미치는 영향을 확인하기 위하여 다음과 같이 실험을 실시하였다. In order to confirm the effect of wheatgrass hot water extract on the production of testosterone, the male hormone, the experiment was conducted as follows.
TM3 세포에 밀싹 열수 추출물 동결건조 분말을 물 (DDW, distilled deionized water)에 잘 녹인 후, 각각 0, 1, 10, 25, 50ug/ml의 농도로 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 1%, fetal bovine serum 0.5%에 녹여서 48시간동안 처리한 뒤, testosterone의 양을 측정하고자 세포 배양액 상등액을 수득하여 96 웰 플레이트에 분주하였다. 그 다음 제조사의 지침에 따라 테스토스테론 측정용 ELISA 키트(Testosterone ELISA kit, R &D systems, Cat.# KGE010)를 사용하여, 세포 배양액 내의 테스토스테론의 양(pg/ml)을 측정하였다.After dissolving the lyophilized powder of the hot water extract of wheatgrass in TM3 cells in water (DDW, distilled deionized water), a 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's at concentrations of 0, 1, 10, 25, and 50 ug/ml, respectively. After dissolving in medium,
이에 대한 결과를 도 3에 나타내었다. The results for this are shown in FIG. 3 .
도 3에 나타낸 바와 같이, 밀싹 열수 추출물은 고환 세포주 TM3에서 미처리 대조군 대비 테스토스테론의 분비량을 현저히 증가시키는 것으로 확인 이 되었다. As shown in FIG. 3 , it was confirmed that wheat sprout hot water extract significantly increased the secretion of testosterone in the testicular cell line TM3 compared to the untreated control group.
이상의 결과를 통해, 밀싹 추출물이 테스토스테론 저하에 의한 남성 갱년기 증상에 예방 또는 치료효과를 나타낼 수 있을 것으로 판단해 볼 수 있었다. Through the above results, it could be judged that wheatgrass extract could have a preventive or therapeutic effect on male menopausal symptoms caused by low testosterone.
본 발명이 제공하는 밀싹 추출물은 남성 호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론 분비 촉진 효과를 나타내어 남성 갱년기 증후군 치료제 또는 개선용 식품 개발에 매우 유용하게 활용이 될 수 있어 산업상 이용가능성이 매우 우수하다.The wheatgrass extract provided by the present invention increases the expression of male hormone-related genes and proteins and exhibits a testosterone secretion promoting effect, so it can be very usefully used in the development of food for treatment or improvement of male menopausal syndrome, and thus has excellent industrial applicability. do.
Claims (8)
A pharmaceutical composition for preventing or treating male menopausal syndrome comprising wheatgrass extract as an active ingredient.
A food composition for preventing or improving male menopausal syndrome comprising wheatgrass extract as an active ingredient.
The method according to claim 1 or 2, wherein the male menopause syndrome is hypogonadism, enlarged prostate, lower urinary tract symptoms, nervousness, emotional anxiety, depression, hot flashes, sleep disorders, decreased vitality, decreased work capacity, decreased libido, A composition, characterized in that at least one selected from the group consisting of erectile dysfunction, decreased stamina, decreased physical strength, decreased exercise capacity, decreased body hair and decreased testosterone.
The composition according to claim 1 or 2, wherein the male menopausal syndrome is hypotestosterone.
The composition according to claim 1 or 2, wherein the wheat sprout extract is an extract of wheat sprout water, an organic solvent, or a mixture thereof.
The composition according to claim 5, wherein the organic solvent is an alcohol having 1 to 6 carbon atoms.
A male hormone secretagogue containing wheatgrass extract as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200030851A KR20210115294A (en) | 2020-03-12 | 2020-03-12 | Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200030851A KR20210115294A (en) | 2020-03-12 | 2020-03-12 | Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210115294A true KR20210115294A (en) | 2021-09-27 |
Family
ID=77925309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200030851A KR20210115294A (en) | 2020-03-12 | 2020-03-12 | Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20210115294A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102445830B1 (en) | 2022-03-28 | 2022-09-21 | 주식회사 사임당화장품 | Cosmetic Compositions for Skin Moisture Comprising Extract of Triticum aestivum |
| KR20230128415A (en) | 2022-02-26 | 2023-09-05 | 주식회사 아리바이오에이치앤비 | Immune boosting composition using wheat germ containing organic germanium |
-
2020
- 2020-03-12 KR KR1020200030851A patent/KR20210115294A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230128415A (en) | 2022-02-26 | 2023-09-05 | 주식회사 아리바이오에이치앤비 | Immune boosting composition using wheat germ containing organic germanium |
| KR102445830B1 (en) | 2022-03-28 | 2022-09-21 | 주식회사 사임당화장품 | Cosmetic Compositions for Skin Moisture Comprising Extract of Triticum aestivum |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| JP6403901B2 (en) | Health obesity maintenance agent | |
| KR20220000892A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of barley sprout | |
| WO2017159725A1 (en) | Composition for promoting glp-1 secretion, and method for manufacturing same | |
| KR102189891B1 (en) | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran | |
| JP6294710B2 (en) | Glucose metabolism improver | |
| KR20210115294A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout | |
| US10729737B2 (en) | Muscle-enhancing agent | |
| WO2021025103A1 (en) | Composition for inhibiting reduction of testosterone and/or dihydrotestosterone | |
| KR102187335B1 (en) | Composition for improving premenstrual syndrome symptom comprising compounds isolated from Hordeum vulgare extract | |
| KR102231164B1 (en) | Composition for preventing or treating andropause related symptoms comprising the extract of rice straw | |
| KR101067028B1 (en) | Composition for preventing and treating menopausal syndrome in women containing wild herbs extract | |
| KR102075836B1 (en) | Composition for preventing or treating menopausal syndrome of women comprising Aristotelia chilensis extract, Angelica sinensis extract and Passiflora incarnata extract as an active ingredient | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| JP7481023B2 (en) | Composition for preventing or treating obesity or obesity-induced metabolic syndrome, comprising Enterococcus faecalis as an active ingredient | |
| EP4197549A1 (en) | Composition comprising dead lactic acid bacterial mass as active ingredient for prevention, alleviation, or treatment of prostatic hypertrophy or alopecia | |
| KR20210115289A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of licorice | |
| WO2016133155A1 (en) | α-GLUCOSIDASE INHIBITOR | |
| JP2007070263A (en) | Composition for preventing diabetes mellitus | |
| KR20230017389A (en) | Composition for preventing or treating chronic prostatitis and lower urinary tract symptoms | |
| KR101026523B1 (en) | Pharmaceutical composition and food additives containing extract of black onion for prevention and treatment of overweight or obesity | |
| KR20200085158A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of red clover | |
| KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
| KR102646051B1 (en) | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Gelidium amansii extract | |
| KR102467837B1 (en) | Composition comprising radish sprouts extract including increased isothiocyanate and method for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E601 | Decision to refuse application |